Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02271334 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers
A Phase 2 study, sponsored by Amphastar Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT02271334 is a Phase 2 study that has completed, run by Amphastar Pharmaceuticals. The registered enrollment target is 22 participants.
The verdict
NCT02271334, a Phase 2 study, has completed, sponsored by Amphastar Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the pharmacokinetics (PK) and safety profiles of A006, an Albuterol dry powder inhaler (DPI), following a single dose of 110 mcg (T1) or 220 mcg (T2), in healthy male and female adult volunteers.
Interventions
- DRUG A006 DPI
- DRUG Proventil® MDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02271334
The ClinicalTrials.gov registry entry for NCT02271334 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amphastar Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which A006 DPI is the first listed.
NCT02271334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02271334 about?
NCT02271334 is a clinical study titled "Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers". The objective of this study is to evaluate the pharmacokinetics (PK) and safety profiles of A006, an Albuterol dry powder inhaler (DPI), following a single dose of 110 mcg (T1) or 220 mcg (T2), in healthy male and female adult volunteers.
What is the current status of trial NCT02271334?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2014-08. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02271334?
The interventions under investigation include: A006 DPI (DRUG), Proventil® MDI (DRUG).
Who is sponsoring clinical trial NCT02271334?
This trial is sponsored by Amphastar Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.